Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Author:

Haddad Robert I1,Bischoff Lindsay2,Ball Douglas3,Bernet Victor4,Blomain Erik5,Busaidy Naifa Lamki6,Campbell Michael7,Dickson Paxton8,Duh Quan-Yang9,Ehya Hormoz10,Goldner Whitney S.11,Guo Theresa12,Haymart Megan13,Holt Shelby14,Hunt Jason P.15,Iagaru Andrei5,Kandeel Fouad16,Lamonica Dominick M.17,Mandel Susan18,Markovina Stephanie19,McIver Bryan20,Raeburn Christopher D.21,Rezaee Rod22,Ridge John A.10,Roth Mara Y.23,Scheri Randall P.24,Shah Jatin P.25,Sipos Jennifer A.26,Sippel Rebecca27,Sturgeon Cord28,Wang Thomas N.29,Wirth Lori J.30,Wong Richard J.25,Yeh Michael31,Cassara Carly J.32,Darlow Susan32

Affiliation:

1. 1Dana-Farber/Brigham and Women’s Cancer Center;

2. 2Vanderbilt-Ingram Cancer Center;

3. 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

4. 4Mayo Clinic Cancer Center;

5. 5Stanford Cancer Institute;

6. 6The University of Texas MD Anderson Cancer Center;

7. 7UC Davis Comprehensive Cancer Center;

8. 8St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

9. 9UCSF Helen Diller Family Comprehensive Cancer Center;

10. 10Fox Chase Cancer Center;

11. 11Fred & Pamela Buffett Cancer Center;

12. 12UC San Diego Moores Cancer Center;

13. 13University of Michigan Rogel Cancer Center;

14. 14UT Southwestern Simmons Comprehensive Cancer Center;

15. 15Huntsman Cancer Institute at the University of Utah;

16. 16City of Hope National Medical Center;

17. 17Roswell Park Comprehensive Cancer Center;

18. 18Abramson Cancer Center at the University of Pennsylvania;

19. 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

20. 20Moffitt Cancer Center;

21. 21University of Colorado Cancer Center;

22. 22Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

23. 23Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

24. 24Duke Cancer Institute;

25. 25Memorial Sloan Kettering Cancer Center;

26. 26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

27. 27University of Wisconsin Carbone Cancer Center;

28. 28Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

29. 29O’Neal Comprehensive Cancer Center at UAB;

30. 30Massachusetts General Hospital Cancer Center;

31. 31UCLA Jonsson Comprehensive Cancer Center; and

32. 32National Comprehensive Cancer Network.

Abstract

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Publisher

Harborside Press, LLC

Subject

Oncology

Reference420 articles.

1. The goitrous patient with an elevated serum calcitonin--what to do?;Horvit;J Clin Endocrinol Metab,1997

2. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

3. Update to the College of American Pathologists reporting on thyroid carcinomas;Ghossein;Head Neck Pathol,2009

4. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma;Vitale;J Clin Endocrinol Metab,2000

5. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors;Kouvaraki;Thyroid,2005

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3